三阴性乳腺癌中辅助性卡培他滨治疗：越早越好？ - Suppr | 超能文献

Adjuvant Capecitabine In Triple Negative Breast Cancer: The Earlier, The Better?

作者信息

Guven D C, Taban H, Dizdar O

机构信息

64005Hacettepe University Cancer Institute, Department of Medical Oncology, Ankara, Turkey.

出版信息

J Oncol Pharm Pract. 2022 Jan;28(1):203-204. doi: 10.1177/10781552211045909. Epub 2021 Oct 9.

DOI:10.1177/10781552211045909

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Adjuvant Capecitabine In Triple Negative Breast Cancer: The Earlier, The Better?三阴性乳腺癌中辅助性卡培他滨治疗：越早越好？

J Oncol Pharm Pract. 2022 Jan;28(1):203-204. doi: 10.1177/10781552211045909. Epub 2021 Oct 9.

2

Radiation Recall Dermatitis After Capecitabine in a Patient With Triple Negative Breast Cancer.卡培他滨致三阴性乳腺癌患者放射性皮炎。

Pract Radiat Oncol. 2021 Nov-Dec;11(6):448-452. doi: 10.1016/j.prro.2021.06.001. Epub 2021 Jun 23.

3

[Adjuvant Capecitabine for Residual Disease after Standard Neoadjuvant Chemotherapy Among Patients with Triple-Negative Breast Cancer].三阴性乳腺癌患者标准新辅助化疗后残留病灶的辅助性卡培他滨治疗

Gan To Kagaku Ryoho. 2022 Dec;49(13):1461-1463.

4

The adjuvant use of capecitabine for residual disease following pre-operative chemotherapy for breast cancer: Challenges applying CREATE-X to a US population.在乳腺癌术前化疗后残留疾病中应用卡培他滨辅助治疗：将 CREATE-X 应用于美国人群所面临的挑战。

J Oncol Pharm Pract. 2021 Dec;27(8):1883-1890. doi: 10.1177/1078155220971751. Epub 2020 Nov 5.

5

Is the benefit of using adjuvant capecitabine in patients with residual triple-negative breast cancer related to pathological response to neoadjuvant chemotherapy?辅助卡培他滨在残留三阴性乳腺癌患者中的获益是否与新辅助化疗的病理反应相关？

Expert Rev Anticancer Ther. 2022 Jul;22(7):773-780. doi: 10.1080/14737140.2022.2076670. Epub 2022 Jun 1.

6

Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy.卡培他滨辅助治疗新辅助化疗后的乳腺癌。

N Engl J Med. 2017 Jun 1;376(22):2147-2159. doi: 10.1056/NEJMoa1612645.

7

Advances in the systemic treatment of triple-negative breast cancer.三阴性乳腺癌全身治疗的进展

Curr Oncol. 2018 Jun;25(Suppl 1):S142-S150. doi: 10.3747/co.25.3954. Epub 2018 Jun 13.

8

Capecitabine-induced leukoencephalopathy in a patient with triple-negative breast cancer: A case report and review of the literature.卡培他滨诱发三阴性乳腺癌患者白质脑病：一例报告及文献复习

J Oncol Pharm Pract. 2022 Apr;28(3):703-709. doi: 10.1177/10781552211056856. Epub 2021 Nov 18.

9

Costs per event averted in the neoadjuvant and adjuvant settings of early triple-negative breast cancer.早期三阴性乳腺癌新辅助和辅助治疗中避免发生事件的成本。

Ann Oncol. 2023 Aug;34(8):723-724. doi: 10.1016/j.annonc.2023.06.005.

10

Post-neoadjuvant treatment with capecitabine and trastuzumab emtansine in breast cancer patients-sequentially, or better simultaneously?卡培他滨和曲妥珠单抗恩美曲妥珠单抗新辅助治疗后乳腺癌患者-序贯，还是更好地同时？

Strahlenther Onkol. 2021 Jan;197(1):1-7. doi: 10.1007/s00066-020-01667-z. Epub 2020 Jul 31.

引用本文的文献

1

A cost-effectiveness analysis of capecitabine maintenance therapy versus routine follow-up for early-stage triple-negative breast cancer patients after standard treatment from a perspective of Chinese society.卡培他滨维持治疗与标准治疗后常规随访用于早期三阴性乳腺癌患者的成本效果分析：中国视角。

BMC Med. 2022 Sep 26;20(1):320. doi: 10.1186/s12916-022-02516-9.